Clinical Trial

Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label, single-arm, dose-escalation, and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABO2011 monotherapy or in combination with Toripalimab in patients with advanced solid tumors.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-10-13; most recent amendment 2025-08-18.
Status change: Enrolling by Invitation → Recruiting 2024-04-23
Status change: Recruiting → Enrolling by Invitation 2023-11-01
Trial Details
NCT Number NCT06088004
Lead Sponsor Suzhou Abogen Biosciences Co., Ltd.
Collaborators: Abogen Biosciences (Shanghai) Co., Ltd
Conditions Solid Tumor, Adult
Enrollment 218 participants
Start Date 2023-09-28
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-22